pirenzepine has been researched along with Developmental Psychomotor Disorders in 2 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 9.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| "To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone." | 5.10 | The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia. ( Ames, D; Chiu, E; Hall, K; Harrigan, S; Hassett, A; Macfarlane, S; Mastwyk, M; O'Connor, DW; Opie, J; Ritchie, CW, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, TJ | 1 |
| Zipursky, RB | 1 |
| Perkins, D | 1 |
| Addington, J | 1 |
| Woods, SW | 1 |
| Hawkins, KA | 1 |
| Hoffman, R | 1 |
| Preda, A | 1 |
| Epstein, I | 1 |
| Addington, D | 1 |
| Lindborg, S | 1 |
| Marquez, E | 1 |
| Tohen, M | 1 |
| Breier, A | 1 |
| McGlashan, TH | 1 |
| Ritchie, CW | 1 |
| Chiu, E | 1 |
| Harrigan, S | 1 |
| Hall, K | 1 |
| Hassett, A | 1 |
| Macfarlane, S | 1 |
| Mastwyk, M | 1 |
| O'Connor, DW | 1 |
| Opie, J | 1 |
| Ames, D | 1 |
2 trials available for pirenzepine and Developmental Psychomotor Disorders
| Article | Year |
|---|---|
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Comorbidity; Depressive | 2003 |
The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Female; Humans; Male; Middle Aged; O | 2003 |